Article thumbnail

Relevance of VEGF and Nephrin Expression in Glomerular Diseases

By Claudia A. Bertuccio


The glomerular filtration barrier is affected in a large number of acquired and inherited diseases resulting in extensive leakage of plasma albumin and larger proteins, leading to nephrotic syndrome and end-stage renal disease. Unfortunately, the molecular mechanisms governing the development of the nephrotic syndrome remain poorly understood. Here, I give an overview of recent investigations that have focused on characterizing the interrelationships between the slit diaphragm components and podocytes-secreted VEGF, which have a significant role for maintaining the normal podocyte structure and the integrity of the filtering barrier

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A preeclampsialike syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib,”
  2. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,”
  3. A VEGF-A splice variant defective for heparan sulfate and neuropilin1 binding shows attenuated signaling through
  4. (2000). Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascularendothelialgrowthfactorinhumanmesangialcells,”
  5. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,”
  6. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis,”
  7. (2001). Astr¨ om et al., “Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy,”
  8. (2006). Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP,”
  9. (2010). Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans,”
  10. (2003). Baelde et al., “Expression of podocyte-associated molecules in acquired human kidney diseases,”
  11. (2008). Berg´ e ,D .A l l a n i c ,G .T o b e l e m ,a n d T. Merkulova-Rainon, “Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity,”
  12. (2002). CD2-associated protein directly interacts with the actin cytoskeleton,”
  13. (2000). Cell signaling by receptor tyrosine kinases,”
  14. (2005). Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose,”CurrentCancerDrugTargets,vol.5,no.7,pp.551–559,
  15. (1999). Congenital nephrotic syndrome in mice lacking CD2-associated protein,”
  16. (1991). Current status of the structural and functional basis of glomerular filtration and proteinuria,”
  17. (2006). De Vriese, “A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat,”
  18. (2004). De Vriese, “The role of vascular endothelial growth factor (VEGF)
  19. (2000). Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis,”
  20. defines a novel family of podocin interacting proteins,”
  21. (2008). Dei Cas et al., “Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice,”
  22. (2004). Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein,”
  23. (2002). Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis,”
  24. (2000). e i s e r ,W .K r i z ,M .K r e t z l e r ,a n dP .M u n d e l ,“ T h eg l o m e r u -lar slit diaphragm is a modified adherens junction,”
  25. (2010). Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome,”
  26. (2001). Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome,”
  27. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy,”
  28. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,”
  29. (2004). Expression of human nephrin mRNA in diabetic nephropathy,”
  30. (2004). Expression of nephrin in acquired forms of nephritic syndrome in childhood,”
  31. (2002). Expression of nephrin in acquired human glomerular disease,”
  32. (2001). Expression of nephrin in pediatric kidney diseases,”
  33. (2003). Expression of nephrin, podocin, α-actinin, and WT1 in children with nephritic syndrome,”
  34. (1998). Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis,”
  35. (1995). Expression of vascularendothelialgrowthfactoranditsreceptorsinhuman renal ontogenesis and in adult kidney,”
  36. (2007). Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma,”
  37. (2006). Expression profile of nephrin, podocin, and CD2AP in chinesechildrenwithMCNSandIgAnephropathy,”Pediatric Nephrology,
  38. (2001). FAT is a component of glomerular slit diaphragms,”
  39. (2003). Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes,”
  40. (2006). Furuichi et al., “Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis,”
  41. (2003). Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin,”
  42. (1998). Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) Receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors,”
  43. (2008). Glomerular endothelium in kidneys with congenital nephrotic syndrome of the finnish type (NPHS1),”
  44. (2007). Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia,” Nephrology Dialysis Transplantation,v o l .2 2 ,n o .4 ,p p .
  45. (1999). Glomerular expression of nephrin is decreased in acquired human nephritic syndrome,”
  46. (2010). Glomerular structure and function require paracrine, not autocrine, VEGFVEGFR-2 signaling,”
  47. (2003). Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases,”
  48. (1991). Glomerulogenesis in the developing kidney,”
  49. (2008). Goishi et al., “Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization,”
  50. (2010). Gr¨ unwald et al., “Renal side effects of VEGF-blocking therapy,”
  51. (1996). Heterozygous embryonic lethality induced by targeted inactivation
  52. (2003). Homodimerizationandheterodimerizationoftheglomerular podocyte proteins nephrin and NEPH1,”
  53. (1996). i m p la n dJ .C .B r o w n ,“ S u p r a m o l e c u l a ra s s e m b l yo f basement membranes,”
  54. (1984). Identification and characterization of podocalyxin, the major sialoprotein of the renal glomerular epithelial cell,”
  55. (1991). Identification of a new endothelial cell growth factor receptor tyrosine kinase,”
  56. (2007). Impaired glomerular maturation and lack of VEGF165b in DenysDrash syndrome,”
  57. (1999). Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor
  58. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,”
  59. (2001). K¨ o t t g e n ,B .S c h i l l i n g ,G .W a l z ,a n dT .B e n z -ing, “Interaction with Podocin facilitates nephrin signaling,”
  60. (2001). Lindstr¨ o m ,A .M .B l o m
  61. localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain,”
  62. (1998). M¨ annikk¨ o et al., “Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome,”
  63. (1995). Management of congenital nephrotic syndrome of the finnish type,”
  64. (2003). Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype,”
  65. (2000). Minamino et al., “Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with
  66. (2010). Modulation of Notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy,”
  67. (1996). Molecular properties of the glomerular basement membrane,”
  68. (2006). Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier,”
  69. (2000). Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis,”
  70. (2002). N-linked glycosylation is critical for the plasma membrane localization of nephrin,”
  71. (2006). Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes,”
  72. (2002). Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy,”
  73. (2003). Nephrin expression is reduced in human diabetic nephropathy,”
  74. (2004). Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome
  75. (1999). Nephrin is specifically located at the slit diaphragm of glomerular podocytes,”
  76. (1999). Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney,”
  77. (2001). Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome,”
  78. (2004). Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography,”
  79. (2003). Neutralizationofcirculatingvascularendothelialgrowthfactor(VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt1) induces proteinuria,”
  80. (2000). NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome,”
  81. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely relatd to the fms family,”
  82. (2001). omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin,”
  83. (2010). Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease,”
  84. (2002). Patterns of nephrin and a new proteinuria-associated protein expression in human renal diseases,”
  85. Placenta growth factor. potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR,”
  86. (2001). Podocin, a raftassociated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin,”
  87. (2001). Podocyte proteins in galloway-mowat syndrome,”
  88. (2009). Predisposition to relapsing nephrotic syndrome by a nephrin mutation that interferes with assembly of functioning microdomains,”
  89. (2000). Primary structure of mouse and rat nephrin cDNA and structure and expression of the mouse gene,”
  90. (2008). Properties of the glomerular barrier and mechanisms of proteinuria,”
  91. (2001). Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to
  92. (2000). R a a t s ,J .v a nd e nB o r n ,M .A .B a k k e re ta l . ,“ E x p r e s s i o n of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies,”
  93. (2008). r e m i n a
  94. (2003). randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,”
  95. (1998). Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites,”
  96. (2009). Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats,”
  97. (2011). Renal involvement in preeclampsia: similarities to VEGF ablation therapy,”
  98. (2007). Role of the VEGF—a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier,”
  99. (2005). S.Chen,J.S.Lee,M.C.Iglesias-delaCruzetal.,“Angiotensin IIstimulatesα3(IV)collagenproductioninmousepodocytes via TGF-β and VEGF signalling: implications for diabetic glomerulopathy,”
  100. (2004). Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy,”
  101. (1987). Structure and development of the glomerular capillary wall and basement membrane,”
  102. (2003). T.B.Huber,B.Hartleben,J.Kimetal.,“NephrinandCD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling,”
  103. (2008). The alternatively spliced anti-angiogenic family of VEGF isoforms VEGF xxxb in human kidney development,”
  104. (2009). The balance of autocrine VEGFA and VEGF-C determines podocyte survival,”
  105. (2003). The carboxyl terminus of neph family members binds to the PDZ domain protein zonula occludens-1,”
  106. (2006). The endogenous anti-angiogenic family of splice variants of VEGF, VEGF xxxb, are down-regulated in pre-eclamptic placentae at term,”
  107. (2001). The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death,”
  108. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis,”
  109. (1990). The tight junction protein ZO-1 is concentrated along slit diaphragms of the glomerular epithelium,” J o u r n a lo fC e l lB i o l o g y ,
  110. (1991). The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing
  111. (2005). TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function,”
  112. (1988). Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytesofchicken,rat,andman,”LaboratoryInvestigation,
  113. (1999). Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm,”
  114. (1999). Vascular endothelial growth factor (VEGF) and its receptors,”
  115. (2005). Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy,”
  116. (2005). Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes,”
  117. (1997). Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis,”
  118. (2004). Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats,”
  119. (1999). Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation,”
  120. (2008). VEGF-A splicing: the key to antiangiogenic therapeutics?”
  121. (2008). VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy,”
  122. (2002). VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma,”
  123. (2004). VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and8
  124. (1996). α 3 β 1 integrin has a crucial role in kidney and lung organogenesis,”